Europe begins a pilot for earlier expert input on breakthrough medical devices
The EMA programme gives selected high-risk devices a route to scientific advice before wider expansion in 2027.
Anecdotal editorial image
The answer first
The European Medicines Agency launched a 2026 pilot that lets selected manufacturers seek expert-panel input on breakthrough status and clinical evidence for high-risk medical devices.
Why it matters
Wellness and diagnostics increasingly overlap with regulated devices. The pilot illustrates how evidence review differs from consumer-product launch language.
How the pilot works
The programme offers selected manufacturers an expert view on whether a device qualifies as breakthrough technology and advice on the clinical evidence needed under the EU Medical Device Regulation.
An initial phase runs through July 2026. A broader application window begins in September, with later phases expected to cover additional device classes.
Why consumers should care
A device can look and feel like a wellness product while making claims that bring it into a regulated category. Regulatory status depends on intended use, evidence and jurisdiction, not simply whether the product is sold in a clinic or app store.
Anecdotal uses those distinctions on device pages so “available,” “cleared,” “CE marked” and “clinically validated” are not treated as interchangeable labels.
Programme information from the European Medicines Agency.
Primary sources
Check the underlying record.
- 01Expert panel support for breakthrough medical devices: pilot programmeregulator
European Medicines Agency · 2026-04-28
Keep following the change
Get the most material diagnostics & devices updates in the free Anecdotal Briefing.
We never sell or share your email. Unsubscribe in one click.
Keep reading
Related intelligence.
DeepSkin receives US clearance as an aesthetic electrical stimulator
The FDA database lists the DEP100 as substantially equivalent in a May 2026 decision.
FDA changes boxed-warning language on six menopause hormone-therapy products
The February decision removed specific cardiovascular, breast-cancer and probable-dementia statements from the most prominent warning box.
The US moringa-powder Salmonella outbreak is over—but recalled products may remain
The FDA and CDC closed the investigation after 131 reported cases across 38 states. The products have long shelf lives.